Balyasny Asset Management
ETON icon

Balyasny Asset Management’s Eton Pharmaceutcials ETON Stock Holding History

Balyasny Asset Management’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,205
Closed -$652K – 2973
2025
Q1 		$652K Buy
50,205
+38,355
+324% +$580K ﹤0.01% 2180
2024
Q4 		$158K Buy
+11,850
New +$120K ﹤0.01% 2561

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Balyasny Asset Management's ETON Position: Q2 2025 in Review

Balyasny Asset Management sold out of Eton Pharmaceutcials (ETON) in Q2 2025, closing a stake of 50,205 shares — an estimated $652K sold.

Balyasny Asset Management first reported a position in ETON in Q4 2024 and held it in 2 quarters. The position peaked at $652K in Q1 2025. 87 funds tracked by Wall St. Rank hold ETON as of Q2 2025.

  • Balyasny Asset Management reported no remaining Eton Pharmaceutcials position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 50,205 Eton Pharmaceutcials shares in Q2 2025, an estimated $652K.
  • Balyasny Asset Management first reported a position in Eton Pharmaceutcials in Q4 2024 and held it in 2 quarters.
  • Balyasny Asset Management's Eton Pharmaceutcials position peaked at $652K in Q1 2025.
  • 87 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.